Pazopanib HCl (GW786034 HCl)

For research use only.

Catalog No.S1035

11 publications

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Pazopanib HCl (GW786034 HCl) has been cited by 11 publications

3 Customer Reviews

  • IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC M{LsSmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1vr[IlvcGmkaYTzJJRp\SCYRVfGMYlv\HWlZXSgdJJwdGmoZYLheIlwdiCxZjDIWXZGS3N? NILFNm4yQDZ{MEO4Ni=>
HUVEC MYjLbY5ie2ViYYPzZZk> NIm0WmNqdmirYnn0d{BXTUeILXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIG\FS2ZTNTJiaX6gTHVXTUNiY3XscJMhf2m2aDDhckBKSzVyIH;mJQKJxDhibl2= MVmxPFYzODN6Mh?=
MM NH30[GJMcW6jc3WgZZN{[Xl? M{HFNYlvcGmkaYTzJHZGT0ZvaX7keYNm\CCyaH;zdIhwenmuYYTpc44hd2ZiZnz0NS=> NHG1RogyPzF4NEOzNi=>
MM.1S MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NXjxTIlbOTBizsznM41N NYX5OYlVcW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= M{\vflE4OTZ2M{Oy
MM.1R NF;t[YtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NXjhPG9DOTBizsznM41N NWPGd4V1cW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= NWj2NlBtOTdzNkSzN|I>
RPMI M331PGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NW[ySoN{OTBizsznM41N NGr0NXpqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= NWjYcZpmOTdzNkSzN|I>
Dox40 MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NYHvSpk6OTBizsznM41N MV3pcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? NHG2T3cyPzF4NEOzNi=>
INA-6 MlfUS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NXHXPWxTOTBizsznM41N M{LzTolvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq Mn\LNVcyPjR|M{K=
OPM2 MlPJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MljlNVAh|rypL33M M3TiOYlvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq MXmxO|E3PDN|Mh?=
U266 MnjpS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MnfhNVAh|rypL33M MmPkbY5pcWKrdIOgUW0hS2WubDDHdo94fGh? NIGyTpkyPzF4NEOzNi=>
MM.1S MUjjfZRwfG:6aXPpeJkh[XO|YYm= M3TvSlIxKM7:Zz;tUC=> M4nj[olvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= M{niOlE4OTZ2M{Oy
MM.1R MVjjfZRwfG:6aXPpeJkh[XO|YYm= NH[0dHYzOCEQvHevcWw> NEP4XG5qdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs MkXnNVcyPjR|M{K=
RPMI MnXnZ5l1d3SxeHnjbZR6KGG|c3H5 M1nkblIxKM7:Zz;tUC=> MojibY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= M4jjR|E4OTZ2M{Oy
Dox40 NXvPdmJn[3m2b4TvfIlkcXS7IHHzd4F6 Mo\aNlAh|rypL33M Mn\qbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= NH\QSWoyPzF4NEOzNi=>
INA-6 NWTFOoxi[3m2b4TvfIlkcXS7IHHzd4F6 MWeyNEDPxGdxbVy= NW\XR5lYcW6qaXLpeJMhVU1iQ3XscEBUfXK4aY\hcC=> MUOxO|E3PDN|Mh?=
OPM2 NFK2UGJkgXSxdH;4bYNqfHliYYPzZZk> NV7mT2NwOjBizsznM41N MUXpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu MXuxO|E3PDN|Mh?=
U266 NU\xc5ln[3m2b4TvfIlkcXS7IHHzd4F6 NHT4RZIzOCEQvHevcWw> NHnGWGRqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs NVXodpBZOTdzNkSzN|I>
MM.1S NHjiSXJHfW6ldHnvckBie3OjeR?= Mmr5d5VxeHKnc4Pld{BXTUeILVnu[JVk\WRiRX7kc5Rp\WyrYXygR4VtdCCScn;sbYZmemG2aX;uJIFv\CCPaXfyZZRqd25w NFHrTFEyPzF4NEOzNi=>
MM.1R MXvGeY5kfGmxbjDhd5NigQ>? NV7XdGlbe3WycILld5NmeyCYRVfGMWlv\HWlZXSgSY5ld3SqZXzpZYwhS2WubDDQdo9tcW[ncnH0bY9vKGGwZDDNbYdz[XSrb36u MmHPNVcyPjR|M{K=
Dox40 NGXKN3NHfW6ldHnvckBie3OjeR?= NVjzbndJe3WycILld5NmeyCYRVfGMWlv\HWlZXSgSY5ld3SqZXzpZYwhS2WubDDQdo9tcW[ncnH0bY9vKGGwZDDNbYdz[XSrb36u MUOxO|E3PDN|Mh?=
OPM2 MYjGeY5kfGmxbjDhd5NigQ>? MX\zeZBxemW|c3XzJHZGT0ZvSX7keYNm\CCHbnTveIhmdGmjbDDD[YxtKFC{b3zp[oVz[XSrb36gZY5lKE2rZ4LheIlwdi5? NHziUFcyPzF4NEOzNi=>
HBMEC NFyzTHFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NUXWfpJohjFyIN88US=> M3y1SGROW09? NHX2O5FKSzVyPUGg{txO MVKyNVA5OTZ3Nh?=
HBMEC MmTWSpVv[3Srb36gZZN{[Xl? M3PsSp4yKM7:TR?= NHHhcZBFVVOR NXWw[ZFQ[WK{b3fheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gWmVITlJ{IIfpeIgh\Gm|coXweIlwdiCxZjDkc5dve3S{ZXHtJHBNS87|MR?= MnnpNlExQDF4NU[=
HBMEC M2XQR2Z2dmO2aX;uJIF{e2G7 MmTSglEh|ryP NYDYZXJFTE2VTx?= Mn\x[Il{enWydIOgeIhmKFKjcz3SZYYuTVKNIIDheIh4[XlidHjyc5VocCCmZXPy[YF{\WRicHjvd5Bpd3K7bHH0[YQhVUWNMT:yJIFv\CCHUluxM|I> MUOyNVA5OTZ3Nh?=
HBMEC MkH1SpVv[3Srb36gZZN{[Xl? MlPCglIxKM7:TR?= NYi4UXg6TE2VTx?= Mmnk[Il{enWydIOgOVAmKG:oIIT1ZoUh\m:{bXH0bY9vKGG2IEGg{txO NWXlXFVsOjFyOEG2OVY>
MDA-MB-231 NFLl[HlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NV63boNbhjFyIN88US=> Mn;uSG1UVw>? M{XocGlEPTB;NTFOwG0> NHjUV5AzOTB6MU[1Oi=>
MDA-MB-231 NUO4OI0zTnWwY4Tpc44h[XO|YYm= MX6wMlUh|ryP NHf3fVZFVVOR NEX4fYJqdmirYnn0d{B1cGViRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6 MoSwNlExQDF4NU[=
MDA-MB-231 NU[3RYVWTnWwY4Tpc44h[XO|YYm= M2\C[lUh|ryP MW\EUXNQ MWXpcoR2[2W|IHGgZ4VtdC2leXPs[UBienKnc4S= MnrINlExQDF4NU[=
J82 M4m5d4N6fG:2b4jpZ4l1gSCjc4PhfS=> NGe1VJZ,OTBizszN NHPRWXhFVVOR MoDRTWM2OD1{ND61O{DPxE1? NX\JNItFOjF3Mkm5NFA>
T24 MVnjfZRwfG:6aXPpeJkh[XO|YYm= MkLIglExKM7:TR?= MorSSG1UVw>? MUDJR|UxRTV{LkS1JO69VQ>? M1O3W|IyPTJ7OUCw
HT1376 Mn3kZ5l1d3SxeHnjbZR6KGG|c3H5 NUnQdpdwhjFyIN88US=> NF34PXRFVVOR NV7xWYtQUUN3ME2yPE4zOSEQvF2= M17rR|IyPTJ7OUCw
RT4 MlqxZ5l1d3SxeHnjbZR6KGG|c3H5 NV\Me3JPhjFyIN88US=> NFzyUoVFVVOR MVrJR|UxRTVwMUSg{txO M1LweFIyPTJ7OUCw
CRL1749 M2PvTYN6fG:2b4jpZ4l1gSCjc4PhfS=> M1S3c54yOCEQvF2= MVLEUXNQ NWXKeXlDUUN3ME2yNk43QSEQvF2= MWGyNVUzQTlyMB?=
HTB9 MkG3Z5l1d3SxeHnjbZR6KGG|c3H5 NFHuU5d,OTBizszN MXLEUXNQ MX3JR|UxRTFzLki0JO69VQ>? MYmyNVUzQTlyMB?=
Sup MVPjfZRwfG:6aXPpeJkh[XO|YYm= NFLN[VN,OTBizszN M4mySWROW09? MWrJR|UxRTV|LkOyJO69VQ>? MX6yNVUzQTlyMB?=
HTB3 NVPhc3Np[3m2b4TvfIlkcXS7IHHzd4F6 MUT+NVAh|ryP NGm0cmRFVVOR NHvqNXhKSzVyPUG0MlE3KM7:TR?= NHL4WFIzOTV{OUmwNC=>
CEC M1TncWZ2dmO2aX;uJIF{e2G7 M2\jZZ4yOCEQvHevcWw> MoLOSG1UVw>? MX;kc5dvNXKnZ4XsZZRmeyCYRVfGJIxmfmWucx?= NFLBb4IzOTZ{MEiyNi=>
RPE M{LFcWZ2dmO2aX;uJIF{e2G7 M1jUS54yOCEQvHevcWw> MWHEUXNQ NW\tV49Q\G:5bj3y[Yd2dGG2ZYOgWmVITiCuZY\lcJM> MX2yNVYzODh{Mh?=
CEC NWP3O2NLTnWwY4Tpc44h[XO|YYm= NI\sRXh,PSEQvHevcWw> NFP5VnVFVVOR NG\5VFljdG:la4Og[Y5ld3SqZXzpZYwh[2WubDDtbYdz[XSrb36= M4TKWlIyPjJyOEKy
5637 MnO4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M1;yRWROW09? NFu3TZBKSzVyPUG1MlDjiIoQvF2= Mn;2NlM5QDd4MEW=
J82 NGLFbHNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1T2W2ROW09? Ml;ETWM2OD1zOD605qCK|ryP NGflWHMzOzh6N{[wOS=>
5637 M{TBd2F2fG:yaHHnfUBie3OjeR?= NH;UXYwzOCEQvF2= NYXLdHRlTE2VTx?= MknPeJJq\2encoOgeIhmKGG3dH;wbIFocWNicILvZ4V{ew>? MnrvNlM5QDd4MEW=
J82 MYHBeZRweGijZ4mgZZN{[Xl? MkLhNlAh|ryP MlX4SG1UVw>? NVz1ZnV6fHKrZ3fldpMhfGinIHH1eI9xcGGpaXOgdJJw[2W|cx?= NYOzb445OjN6OEe2NFU>
5637 MYTGeY5kfGmxbjDhd5NigQ>? NFjncnczOCEQvF2= M3fzUWROW09? MnnObY5lfWOnczDsfZNwe2:vYXyt[IVx\W6mZX70JI5m[3Kxc3nz NWXNZoR1OjN6OEe2NFU>
J82 M3nocmZ2dmO2aX;uJIF{e2G7 NVjH[Y5xOjBizszN M3rvdGROW09? MmPEbY5lfWOnczDsfZNwe2:vYXyt[IVx\W6mZX70JI5m[3Kxc3nz MXqyN|g5PzZyNR?=
5637 NFfBN45HfW6ldHnvckBie3OjeR?= M1LjO|IxKM7:TR?= M4LkbmROW09? M2LiSolv\HWlZYOgcJl{d3OxbXWgZYx1\XKjdHnvckBidmRiaX7obYJqfHNiQ1KgZYN1cX[rdIm= NUTWRYl[OjN6OEe2NFU>
J82 MULGeY5kfGmxbjDhd5NigQ>? MV6yNEDPxE1? M1HpN2ROW09? M3\nb4lv\HWlZYOgcJl{d3OxbXWgZYx1\XKjdHnvckBidmRiaX7obYJqfHNiQ1KgZYN1cX[rdIm= MmrqNlM5QDd4MEW=
KATO-II NUfLNnBnT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NHy0XlQ2KM7:TR?= MmHrSG1UVw>? M{m0coJtd2OtczDwdo9tcW[ncnH0bY9v MUGyOVI1QTV3Nx?=
OCUM-2M NGn4XpRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M3fjSVUh|ryP Mm\pSG1UVw>? MlzlZoxw[2u|IIDyc4xq\mW{YYTpc44> MYeyOVI1QTV3Nx?=
SNU-16 MYLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVe1JO69VQ>? NGjUUplFVVOR NWH3eFAx[myxY3vzJJBzd2yrZnXyZZRqd25? MXuyOVI1QTV3Nx?=
HSC-39 Mnq0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHTTTHk2KM7:TR?= MkPCSG1UVw>? M4rZdIJtd2OtczDwdo9tcW[ncnH0bY9v M4XYeFI2OjR7NUW3
KATO-II MWTjfZRwfG:6aXPpeJkh[XO|YYm= Mn;CglExKM7:TR?= NISzbXFFVVOR MnHYTWM2OD1yLkGgeI8hOi5yIN88cY9tN0x? NH3ZWYEzPTJ2OUW1Oy=>
OCUM-2M M3rDeYN6fG:2b4jpZ4l1gSCjc4PhfS=> M1LNbJ4yOCEQvF2= MV7EUXNQ MljvTWM2OD1yLkGgeI8hOi5yIN88cY9tN0x? MlzCNlUzPDl3NUe=
SNU-16 M3XJ[YN6fG:2b4jpZ4l1gSCjc4PhfS=> NUDsOlVZhjFyIN88US=> MYrEUXNQ NX3m[FM5UUN3ME2wMlEhfG9iMj6wJO69dW:uL1y= NGL2PW8zPTJ2OUW1Oy=>
HSC-39 NH2zTo1kgXSxdH;4bYNqfHliYYPzZZk> M4i3cJ4yOCEQvF2= NUnHVYxNTE2VTx?= NYfh[|dkUUN3ME2wMlEhfG9iMj6wJO69dW:uL1y= MYiyOVI1QTV3Nx?=
NIH 3T3 M3jvU2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NYrzfXFjhjFyIN88US=> MoDtSG1UVw>? NHPSUVBqdmirYnn0d{Bk\WyuIHfyc5d1cCCjbnSgZ49td267IH\vdo1ifGmxbh?= MX[yOVI1QTV3Nx?=
KATO-III NXG2VndITnWwY4Tpc44h[XO|YYm= M3fjeVEh|ryP M3jyeWROW09? MXnpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2 NIjkV4wzPTJ2OUW1Oy=>
OCUM-2M M1jUd2Z2dmO2aX;uJIF{e2G7 M1;2SFEh|ryP MWHEUXNQ NH\XWWdqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0 NHXQS3EzPTJ2OUW1Oy=>
KATO-III NFLKcFdCeG:ydH;zbZMh[XO|YYm= NV3KNXhVOSEQvF2= NUOwTY03TE2VTx?= MXjpcoR2[2W|IHHwc5B1d3Orcx?= NIO1e5QzPTJ2OUW1Oy=>
OCUM-2M NGTYZ3dCeG:ydH;zbZMh[XO|YYm= MnjuNUDPxE1? M3fBU2ROW09? NFWzTVBqdmS3Y3XzJIFxd3C2b4Ppdy=> MVOyOVI1QTV3Nx?=
KATO-III NFvscIJHfW6ldHnvckBie3OjeR?= NUHRSG97OSEQvF2= M2LudGROW09? NFSxSXdqdmirYnn0d{BHT0[UMjDwbI9{eGixconsZZRqd25iYX7kJIRwf26|dILlZY0he2mpbnHsbY5oKG2xbHXjeYxmew>? NHzxcHYzPTJ2OUW1Oy=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / PUMA; 

PubMed: 27924057     


The expression of p53 or PUMA by western blotting analysis in HCT-116 cells treated with (left) 20 μM pazopanib for indicated hours or (right) with 1-20 μM pazopanib for 24 hours.

p-Akt / Akt ; 

PubMed: 27924057     


Akt is inhibited after pazopanib treatment in colon cells. The expression of P-Akt (S473) was detected by western blotting in RKO or HT-29 cells after 20 μM pazopanib treatment for indicated times.

p-VEGFR2 / p-c-Kit / p-PDGFRβ / FLT-3 ; 

PubMed: 19844230     


Inhibition of receptor autophosphorylation by various tyrosine kinase inhibitors. To compare the activities of pazopanib, sunitinib, and sorafenib, we evaluated their inhibitory effects against wild-type VEGFR-2, c-Kit, PDGFR-β, and Flt-3 receptors in HUVEC (for VEGFR-2), NCI-H526 (c-Kit), HFF (PDGFR-β), and RS4;11 (Flt-3). Cells were serum-starved overnight and then treated with DMSO or different concentrations of pazopanib, sunitinib, or sorafenib for 2 h. Cells were then stimulated with respective ligands as described in the cellular autophosphorylation section under Materials and Methods. Total receptor was immunoprecipitated using antireceptor antibodies and phosphorylation was detected using anti-pTyr antibody following western blot analysis.

27924057 19844230
Immunofluorescence
YAP/TAZ; 

PubMed: 26199863     


Dasatinib, fluvastatin, and pazopanib inhibited the nuclear localization of YAP and TAZ. MDA-MB-231 cells were treated with inhibitors for 8 h and YAP and TAZ were visualized by immunofluorescence. (i) Representative images of immunofluorescence. Bar represents 10 μm.

26199863
Growth inhibition assay
Cell viability; 

PubMed: 27924057     


Cell viability was analyzed using Cell Counting Kit-8 at 0, 3, 6, 12 and 24 hours after 1, 5, 10, or 20 μM pazopanib treatment in HCT-116 cells. Data represent the mean ± SEM of four independent experiments.

27924057
In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research:

[1]

- Collapse
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)
Animal Research:

[2]

- Collapse
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
in solvent
Synonyms N/A
Smiles Cl.C[N]1N=C2C=C(C=CC2=C1C)N(C)C3=NC(=NC=C3)NC4=CC=C(C)C(=C4)[S](N)(=O)=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03735758 Recruiting Drug: pazopanib or guideline conform chemotherapy Soft Tissue Sarcoma Adult GWT-TUD GmbH November 2 2018 Phase 4
NCT03334409 Recruiting Drug: Ascorbic Acid|Drug: Pazopanib Hydrochloride Clear Cell Renal Cell Carcinoma|Metastatic Clear Cell Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v7|Unresectable Renal Cell Carcinoma Academic and Community Cancer Research United|National Cancer Institute (NCI) February 16 2018 Phase 2
NCT03149120 Withdrawn Biological: Nivolumab|Drug: Pazopanib Soft Tissue Sarcomas NYU Langone Health|Bristol-Myers Squibb August 2017 Phase 2
NCT03091465 Completed -- Metastatic Renal Cell Carcinoma Spanish Oncology Genito-Urinary Group December 20 2016 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy GW786034|GW786034 ic50|GW786034 price|GW786034 cost|GW786034 solubility dmso|GW786034 purchase|GW786034 manufacturer|GW786034 research buy|GW786034 order|GW786034 mouse|GW786034 chemical structure|GW786034 mw|GW786034 molecular weight|GW786034 datasheet|GW786034 supplier|GW786034 in vitro|GW786034 cell line|GW786034 concentration|GW786034 nmr|GW786034 in vivo|GW786034 clinical trial|GW786034 inhibitor|GW786034 Protein Tyrosine Kinase inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID